Rising Prevalence of Osteoarthritis is Driving Asia-Pacific Osteoarthritis Therapeutics Market

Asia-Pacific osteoarthritis therapeutics market is estimated to grow at a CAGR of 8.8% during the forecast period. Rising prevalence of osteoarthritis is the major factor leveraging market growth. As per the Ministry of Health and Family Welfare (MoHFW), in India, osteoarthritis is the most frequent joint disease with a prevalence of 22% to 39% and is the second most common rheumatologic problem. Osteoarthritis is more common in women compared to men. Approximately 45% of women more than aged 65 years have symptoms while 70% of those more than aged 65 years signifies radiological evidence of osteoarthritis. 

Browse the full report description Asia-Pacific Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report, By Anatomy (Knee, Ankle, Hip, Hand, and Spine), By Drug Type (NSAIDs, Viscosupplementation Agents, Corticosteroids, and Analgesics) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/asia-pacific-osteoarthritis-therapeutics-market

Analgesics are used for osteoarthritis pain treatment; however, they don’t treat inflammation. This drug class works by stopping signals in the body that creates pain. Instances of analgesics include Acetaminophen (Tylenol) and Duloxetine (Cymbalta). Acetaminophen (Tylenol) is an over the counter (OTC) analgesic that can be administered orally as a tablet, gel capsule, or liquid concentration. Another class of drugs is known as nonsteroidal anti-inflammatory drugs (NSAIDs) that are also used for the treatment of pain. As compared to analgesics, NSAIDs also support the prevention of joint damage and painful inflammation. These drugs are regarded as a suitable choice to treat osteoarthritis patients as they are non-sedating and effective. 

Scope of the Asia-Pacific Osteoarthritis Therapeutics Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Anatomy and Drug Type
• Regions Covered- China, India, Japan, and Rest of Asia-Pacific
• Competitive Landscape- Cipla Ltd., Pfizer Inc., GlaxoSmithKline plc, and Sanofi S.A.

Recent Strategic Initiatives in the Asia-Pacific Osteoarthritis Therapeutics Market

• In August 2020, Dr Reddy's Laboratories declared the launch of over-the-counter Diclofenac Sodium topical gel that is used for the treatment of arthritis pain, in the US market. It is the generic version of Voltaren gel by Novartis Corp. This product launch is an essential part of its analgesics portfolio of OTC products. 
• In August 2018, Cipla declared the USFDA approval for Diclofenac Sodium Topical Gel, intended for the pain relief of osteoarthritis of joints including the hands and knees. It is a generic therapeutic equivalent to the reference listed drug (RLD), Voltaren Gel, 1% of GlaxoSmithKline Consumer Health.  

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID-19 forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Asia-Pacific Osteoarthritis Therapeutics Market-Segmentation

By Anatomy

• Knee
• Ankle
• Hip
• Hand
• Spine

By Drug Type

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Viscosupplementation Agents 
• Corticosteroids
• Analgesics

Asia-Pacific Osteoarthritis Therapeutics Market– Segment by Country 

• China
• Japan
• India